A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes
Phase of Trial: Phase I
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Insulin 338 (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 Feb 2013 New trial record